AI + Preclinical Powered
Collaborative Drug Discovery
Unifying advanced computation with translational biology to accelerate breakthrough therapies. Partner with us to move from target to IND with speed, precision, and confidence.
Contact Us
Oncogenix BV
Redefining
Precision Drug Discovery &
Development
Oncogenix BV, headquartered in the Netherlands, is a next-generation biotechnology company which combines deep computational biology, advanced wet-lab capabilities, and translational research expertise to accelerate the discovery and development of novel therapies in Oncology, Autoimmune Disorders, and CNS diseases.
Our mission is to build breakthrough therapeutics that address high-unmet clinical needs—while delivering end-to-end preclinical services that empower biotech and pharma innovators worldwide.
Our Vision
To become Europe’s leading innovation hub for AI-enabled drug discovery, mechanistic biology, and translational development—turning complex biological data into clinically meaningful insights and life-changing therapies.
We bridge advanced computation with state-of-the-art preclinical platforms to accelerate the path from discovery to clinic.
Through collaborative science, rigorous validation, and scalable innovation, we empower partners to develop safer, more effective treatments with unprecedented speed and precision.
What We Offer
Novel Drug Discovery &
Development
We deliver deep, AI-driven understanding of cancer biology by integrating multi-omics data, patient genomics, clinical chemistry, and disease biology into a unified intelligence layer. Our platform systematically maps mutations, signalling pathways, and molecular networks to identify high-confidence targets, clinically relevant biomarkers, and disease-specific vulnerabilities. By contextualizing genomic data with real biological and clinical evidence, we transform complex datasets into actionable insights that guide precision therapy development, patient stratification, and indication selection.
- Target identification & Validation
- Drug Repurposing & Combinations
- Drug Repositioning
- Biomarker Profiling
- Patient Stratification
- Indication Selection
- Companion Diagnostics
- Virtual Clinical Trials
AI-Integrated Mechanistic Biology & Clinical Chemistry Platform validated in our Preclinical Development
Our AI-powered discovery engine bridges computational prediction with rigorous preclinical science. We enable rational drug repurposing, novel target Identification, validation, and mechanism-of-action driven molecule prioritization through virtual screening, toxicity profiling, and predictive efficacy modeling. These insights are seamlessly translated into in-vitro and in-vivo validation using disease-relevant models, ensuring early go/no-go decisions are grounded in biology. This integrated approach reduces attrition, accelerates timelines, and significantly lowers development risk before entering costly clinical stages.
- Virtual Screening (In-Vitro)
- Virtual Screening (In-Vivo)
- Toxicology Profiling/ Virtual Screening
- Cardiotoxicity screening
- Carcinogenicity screening
- Hepatotoxicity
- Neurotoxicity
- Allergic Reactions and Side Effects Matrix
- Preclinical Development including LI/LO and IND enabling studies.
Translational & Clinical Development Acceleration
We extend discovery insights into the clinic through translational intelligence that links molecular biology to patient outcomes. Our platform supports virtual clinical trials, companion diagnostics development, and rational drug-combination strategies to optimize clinical success. By aligning biomarkers, patient selection, and therapeutic hypotheses early, we help partners minimize clinical failure rates, shorten development cycles, and achieve meaningful differentiation in competitive therapeutic landscapes.
- Virtual Clinical Trials and data validation to identify right patient for right Trials
- Inclusion/Exclusion Development
- Companion Diagnostics
- Drug Combination Trials
- Biomarker Validation
Why Oncogenix BV
Oncogenix BV combines computational biology with validated in vitro and in vivo models to identify targets, stratify patients, and
de-risk preclinical programs from target hypothesis to IND-enabling package
Integrated AI +
Wet-Lab Ecosystem
Faster Discovery Cycles,
Higher Predictive
Accuracy
End-to-End
Capabilities
From Molecular
Insights to IND‑Ready
Packages
Focus on High‑
Impact Diseases
Oncology, Autoimmune,
CNS
Collaborative
Approach
Partnering with Biotech,
Pharma & Academic
Institutes
Our Collaboration Model
We bring science, AI, and execution together to convert
innovation into tangible therapeutic value.
Co-Development Partnerships
We collaborate closely with partners to advance drug discovery programs from early target identification through preclinical development. Our co-development model combines your domain expertise with our computational biology, assay development, and wet-lab capabilities to accelerate progress while maintaining full transparency, shared decision-making, and clearly defined milestones.
Joint IP Creation
Our joint IP framework enables fair and transparent ownership of discoveries made together, including novel targets, compounds, and biomarkers. We establish clear IP governance from the start to ensure both parties benefit equitably and can confidently advance, license, or commercialize the resulting innovations.
Risk-Sharing Discovery Models
For high-risk or early-stage programs, we offer shared-risk models that reduce upfront costs and align incentives. Through milestone-based structures or success-linked payments, we help partners pursue promising science while minimizing financial burden and increasing the likelihood of downstream success.
Service-Based Preclinical Programs
Partners can access our preclinical platform through modular service offerings tailored to their needs — from custom assays and organoid models to PK/PD, toxicity, and biomarker studies. This flexible approach allows companies of any size to tap into advanced capabilities without long-term commitment or infrastructure investment.